Incidental resolution of a radiation-induced cavernous hemangioma of the brain following the use of bevacizumab in a child with recurrent medulloblastoma

Pediatric Neurosurgery

Volumn 46, Issue 4, 2010, Pages 303-307

  Aguilera, Dolly ^a   Tomita, Tadanori ^b,c   Goldman, Stewart ^c   Fangusaro, Jason ^c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Bevacizumab; Hemangioma, cavernous; Radiation induced malformation

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; IRINOTECAN; VINCRISTINE;

ARTICLE; BONE MARROW SUPPRESSION; BRAIN DAMAGE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CARCINOMATOUS MENINGITIS; CASE REPORT; CAVERNOUS HEMANGIOMA; CHILD; DRUG SUBSTITUTION; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MAINTENANCE THERAPY; MALE; MEDULLOBLASTOMA; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PRESCHOOL CHILD; PRIORITY JOURNAL; RADIATION DOSE DISTRIBUTION; RADIATION INDUCED NEOPLASM; RECURRENT CANCER; SPINE METASTASIS; TEMPORAL LOBE; TUMOR BLEEDING; TUMOR GROWTH; TUMOR VOLUME;

EID: 78650644217     PISSN: 10162291     EISSN: None     Source Type: Journal    
DOI: 10.1159/000321801     Document Type: Article

References (20)

1. Armstrong GT: Long-term survivors of childhood central nervous system malignancies: the experience of the Childhood Cancer Survivor Study. Eur J Paediatr Neurol 2010; 14: 298-303.
2. Nimjee SM, Powers CJ, Bulsara KR: Review of the literature on de novo formation of cavernous malformations of the central nervous system after radiation therapy. Neurosurg Focus 2006; 21:e4.
3. Strenger V, Sovinz P, Lackner H, et al: Intracerebral cavernous hemangioma after cranial irradiation in childhood: incidence and risk factors. Strahlenther Onkol 2008; 184: 276-280.
4. Heckl S, Aschoff A, Kunze S. Radiation-induced cavernous hemangiomas of the brain: a late effect predominantly in children. Cancer 2002; 94: 3285-3291.
5. Brunon J, Nuti C: Natural history of cavernomas of the central nervous system (in German). Neurochirurgie 2007; 53: 122-130. (Pubitemid 46802640)
6. Keezer MR, Del Maestro R: Radiation-induced cavernous hemangiomas: case report and literature review. Can J Neurol Sci 2009; 36: 303-310.
7. Rigamonti D, Drayer BP, Johnson PC, et al: The MRI appearance of cavernous malformations (angiomas). J Neurosurg 1987; 67: 518-524.
8. Jenab-Wolcott J, Giantonio BJ: Bevacizumab: Current indications and future development for management of solid tumors. Expert Opin Biol The r 2009; 9: 507-517.
9. Summers J, Cohen MH, Keegan P, et al: FDA drug approval summary: bevacizumab plus interferon for advanced renal cell carcinoma. Oncologist 2010; 15: 104-111.
10. Cohen MH, Shen YL, Keegan P, et al: FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist 2009; 14: 1131-1138.
11. Butturini AM, Jacob M, Aguajo J, et al: Highdose chemotherapy and autologous hematopoietic progenitor cell rescue in children with recurrent medulloblastoma and supratentorial primitive neuroectodermal tumors: the impact of prior radiotherapy on outcome. Cancer 2009; 115: 2956-2963.
12. Larson JJ, Ball WS, Bove KE, et al: Formation of intracerebral cavernous malformations after radiation treatment for central nervous system neoplasia in children. J Neurosurg 1998; 88: 51-56.
13. Jung KH, Chu K, Jeong SW, et al: Cerebral cavernous malformations with dynamic and progressive course: correlation study with vascular endothelial growth factor. Arch Neurol 2003; 60: 1613-1618.
14. Kilic T, Pamir MN, Kullu S, et al: Expression of structural proteins and angiogenic factors in cerebrovascular anomalies. Neurosurgery 2000; 46: 1179-1191, discussion 1191-1192.
15. Maeder P, Gudinchet F, Meuli R, et al: Development of a cavernous malformation of the brain. AJNR Am J Neuroradiol 1998; 19: 1141-1143.
16. Hilder TL, Malone MH, Bencharit S, et al: Proteomic identification of the cerebral cavernous malformation signaling complex. J Proteome Res 2007; 6: 4343-4355.
17. Marchuk DA, Srinivasan S, Squire TL, et al: Vascular morphogenesis: tales of two syndromes. Hum Mol Genet 2003; 12:R97-R112.
18. Tirakotai W, Fremann S, Soerensen N, et al: Biological activity of paediatric cerebral cavernomas: an immunohistochemical study of 28 patients. Childs Nerv Syst 2006; 22: 685-691.
19. Mahajan D, Miller C, Hirose K, et al: Incidental reduction in the size of liver hemangioma following use of VEGF inhibitor bevacizumab. J Hepatol 2008; 49: 867-870.
20. Ach T, Thiemeyer D, Hoeh AE, et al: Intravitreal bevacizumab for retinal capillary haemangioma: long-term results. Acta Ophthalmol 2010; 88: 137-138.